{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:25:10Z","timestamp":1783398310469,"version":"3.54.6"},"reference-count":38,"publisher":"The Journal of Rheumatology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,8,20]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the validity of the Juvenile Spondyloarthritis Disease Activity Index (JSpADA) in children with enthesitis-related arthritis (ERA) or juvenile psoriatic arthritis (jPsA) in a prospective clinical trial setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      JUNIPERA (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      :\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03031782\">NCT03031782<\/jats:ext-link>\n                      ) is a phase III, placebo-controlled withdrawal study investigating the safety and efficacy of secukinumab in children with ERA and jPsA. After 12 weeks of open-label treatment with secukinumab, patients were randomized 1:1 to secukinumab or placebo until disease flare or week 52. JSpADA validity was assessed using 3 criteria: convergent validity (Spearman correlation) at week 12 with the Juvenile Arthritis Disease Activity Score in 10 joints (JADAS10), clinical JADAS10 (cJADAS10), and physician global assessment of disease activity (PGA); discriminatory validity at week 12 among patients with active or inactive disease and juvenile idiopathic arthritis American College of Rheumatology response criteria; and responsiveness to change in clinical disease activity from weeks 12 to 52.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At week 12, mean (SD) JSpADA scores showed moderate to good correlation with JADAS10, cJADAS10, and PGA scores (all Spearman \u03c1 &gt; 0.4) and were higher among patients with active vs inactive disease (1.8 [1.3] vs 0.5 [0.8],\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). Patients with improved disease activity from weeks 12 to 52 had greater improvements in JSpADA than patients with worsening disease (\u22120.8 [1.1] vs 0.4 [1.0],\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001); patients with stable disease had minimal change in JSpADA (\u22120.1 [0.5]). Validity results were similar for ERA and jPsA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results validate JSpADA as a disease activity measure for children with ERA and jPsA in a prospective clinical trial setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0294","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T12:25:15Z","timestamp":1757939115000},"page":"85-94","source":"Crossref","is-referenced-by-count":1,"title":["Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting"],"prefix":"10.3899","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-0443","authenticated-orcid":false,"given":"Pamela F.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8407-7782","authenticated-orcid":false,"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1507-9543","authenticated-orcid":false,"given":"Erhard","family":"Quebe-Fehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Shew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2919-3013","authenticated-orcid":false,"given":"Luminita","family":"Pricop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle C.","family":"Pieterse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2987","authenticated-orcid":false,"given":"Hermine I.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"2026010105290842000_53.1.85.1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-021-00332-8","article-title":"Juvenile idiopathic arthritis","volume":"8","author":"Martini","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"2026010105290842000_53.1.85.2","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-021-00629-8"},{"key":"2026010105290842000_53.1.85.3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40744-016-0040-4","article-title":"Juvenile idiopathic arthritis: diagnosis and treatment","volume":"3","author":"Giancane","year":"2016","journal-title":"Rheumatol Ther"},{"key":"2026010105290842000_53.1.85.4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2352-4642(18)30034-8","article-title":"Current and future perspectives in the management of juvenile idiopathic arthritis","volume":"2","author":"Ruperto","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"2026010105290842000_53.1.85.5","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000632"},{"key":"2026010105290842000_53.1.85.6","first-page":"757","article-title":"Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study","volume":"42","author":"Rebollo-Gim\u00e9nez","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"2026010105290842000_53.1.85.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket150"},{"key":"2026010105290842000_53.1.85.8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/OARRR.S261773","article-title":"Current validated clinical and patient reported disease outcome measures in juvenile idiopathic arthritis","volume":"15","author":"Balay-Dustrude","year":"2023","journal-title":"Open Access Rheumatol"},{"key":"2026010105290842000_53.1.85.9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12969-016-0085-5","article-title":"Clinical outcome measures in juvenile idiopathic arthritis","volume":"14","author":"Consolaro","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026010105290842000_53.1.85.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.24516"},{"key":"2026010105290842000_53.1.85.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.34373"},{"key":"2026010105290842000_53.1.85.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204186"},{"key":"2026010105290842000_53.1.85.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev414"},{"key":"2026010105290842000_53.1.85.14","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/art.41879","article-title":"Definition and validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score cutoffs for disease activity states in juvenile idiopathic arthritis","volume":"73","author":"Trincianti","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026010105290842000_53.1.85.15","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1093\/rheumatology\/kead151","article-title":"Paediatric rheumatologists do not score the physician\u2019s global assessment of juvenile idiopathic arthritis disease activity in the same way","volume":"62","author":"Backstr\u00f6m","year":"2023","journal-title":"Rheumatology"},{"key":"2026010105290842000_53.1.85.16","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22411"},{"key":"2026010105290842000_53.1.85.17","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1093\/rheumatology\/key246","article-title":"Prospective validation of the Juvenile Spondyloarthritis Disease Activity Index in children with enthesitis-related arthritis","volume":"57","author":"Zanwar","year":"2018","journal-title":"Rheumatology"},{"key":"2026010105290842000_53.1.85.18","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/14712598.2022.2105140","article-title":"Comparison of the outcomes between early and late anti-tumor necrosis factor therapy in patients with enthesitis-related subcategory of juvenile idiopathic arthritis: a multi-center study in Southeast Asia","volume":"22","author":"Vilaiyuk","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"2026010105290842000_53.1.85.19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.55563\/clinexprheumatol\/1u8y08","article-title":"Secukinumab in the treatment for patients with juvenile enthesitis related arthritis non-responsive to anti-TNF treatment according the Juvenile Spondyloarthritis Disease Activity Index","volume":"40","author":"Baer","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2026010105290842000_53.1.85.20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00296-020-04581-w","article-title":"Capturing the enthesitis related arthritis contemporary profile of Caucasian patients in the era of biologics","volume":"40","author":"Deligeorgakis","year":"2020","journal-title":"Rheumatol Int"},{"key":"2026010105290842000_53.1.85.21","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s10067-017-3733-3","article-title":"Prominent midfoot involvement in children with enthesitis-related arthritis category of juvenile idiopathic arthritis","volume":"36","author":"Phatak","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2026010105290842000_53.1.85.22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5152\/eurjrheum.2019.18180","article-title":"Evaluation of factors affecting the duration of disease-modifying anti-rheumatic drugs application in patients with enthesitis-related arthritis","volume":"6","author":"K\u0131saarslan","year":"2019","journal-title":"Eur J Rheumatol"},{"key":"2026010105290842000_53.1.85.23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220509"},{"key":"2026010105290842000_53.1.85.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222849"},{"key":"2026010105290842000_53.1.85.25","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2010.188946"},{"key":"2026010105290842000_53.1.85.26","first-page":"1058","article-title":"Preliminary definition of disease flare in juvenile rheumatoid arthritis","volume":"29","author":"Brunner","year":"2002","journal-title":"Rheumatol"},{"key":"2026010105290842000_53.1.85.27","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R"},{"key":"2026010105290842000_53.1.85.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.27670"},{"key":"2026010105290842000_53.1.85.29","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"2026010105290842000_53.1.85.30","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20497"},{"key":"2026010105290842000_53.1.85.31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.2.176"},{"key":"2026010105290842000_53.1.85.32","first-page":"1827","article-title":"Responsiveness of clinical measures in children with oligoarticular juvenile chronic arthritis","volume":"26","author":"Ruperto","year":"1999","journal-title":"J Rheumatol"},{"key":"2026010105290842000_53.1.85.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016519"},{"key":"2026010105290842000_53.1.85.34","first-page":"421","article-title":"Responsiveness of clinical measures to flare of disease activity in juvenile idiopathic arthritis","volume":"23","author":"Magni-Manzoni","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2026010105290842000_53.1.85.35","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380802"},{"key":"2026010105290842000_53.1.85.36","first-page":"535","article-title":"Sensitivity to change of rheumatoid arthritis clinical trial outcome measures","volume":"20","author":"Anderson","year":"1993","journal-title":"J Rheumatol"},{"key":"2026010105290842000_53.1.85.37","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90069-5"},{"key":"2026010105290842000_53.1.85.38","doi-asserted-by":"crossref","first-page":"681621","DOI":"10.3389\/fmed.2021.681621","article-title":"Similarities and differences between juvenile and adult spondyloarthropathies","volume":"8","author":"Fisher","year":"2021","journal-title":"Front Med"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T13:29:35Z","timestamp":1767274175000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.3899\/jrheum.2025-0294"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0294","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]}}}